Clinical Laboratory Improvement Amendments (CLIA)
臨床實驗室改進法案(Clinical Laboratory Improvement Amendments,CLIA88)是于1988年頒布的一整套聯邦管理標準,它適用于所有檢測人體標本的臨床檢測項目。但不包括藥物臨床試驗和基礎研究實驗室。
CLIA為各種臨床實驗室檢測設定標準和進行認證。CLIA把臨床實驗室定義為:以診斷、預防或對疾病或損傷的治療提供信息,以及評價人體健康狀態為目的,而對取自人體的標本進行實驗室檢測的任何機構。CLIA的目標之一是保證檢測結果的準確、可靠和及時,而不論這項檢測實在哪里完成的。
在美國,由負責CLIA計劃的實施。CLIA計劃的資金來源是遍布全美的約189,000家臨床實驗室所繳納的會員費。
Clinical Laboratory Improvement Amendments (CLIA) of 1988 are federal regulatory that apply to all testing performed on humans in the United States, except clinical trials and basic research.
CLIA Program
In accord with the CLIA, the CLIA Program sets standards and issues certificates for clinical laboratory testing. CLIA defines a as any facility which performs testing on derived from humans for the purpose of providing information (1) for the , , or treatment of disease or impairment, and (2) for the assessment of health. An objective of the CLIA is to ensure the accuracy, reliability and timeliness of test results regardless of where the test was performed.
(CMS) has the primary responsibility for the operation of the CLIA Program. Within CMS, the program is implemented by the Center for Medicaid and State Operations, Survey and Certification Group, Division of Laboratory Services.
The CLIA Program is funded by user fees collected from approximately 200,000 laboratories, most located in the United States.